Larry A Greenbaum, Nikola Jeck, Günter Klaus, Marc Fila, Cristina Stoica, Sahar Fathallah-Shaykh, Ana Paredes, Larysa Wickman, Raoul Nelson, Rita D Swinford, Carolyn Larkins Abitbol, Mihaela Balgradean, Augustina Jankauskiene, Amandine Perrin, Milica Enoiu, Sun-Young Ahn
BACKGROUND: Pediatric patients with advanced chronic kidney disease (CKD) are often prescribed oral phosphate binders (PBs) for the management of hyperphosphatemia. However, available PBs have limitations, including unfavorable tolerability and safety. METHODS: This phase 3, multicenter, randomized, open-label study investigated safety and efficacy of sucroferric oxyhydroxide (SFOH) in pediatric and adolescent subjects with CKD and hyperphosphatemia. Subjects were randomized to SFOH or calcium acetate (CaAc) for a 10-week dose titration (stage 1), followed by a 24-week safety extension (stage 2)...
May 2021: Pediatric Nephrology